BioSpace News Archive

Tom Richardson, president of ILSE, told BioSpace that it’s a shame how New Jersey is often overlooked as a life sciences hub, particularly when a quick glance at the state’s ecosystem reveals the extensive presence of pharma, biotech and other assets of the industry.

Medigene AG, a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, will present data from the interim analysis of the ongoing Phase I / II clinical trial with Medigene’s DC vaccine during the annual congress of the European Hematology Association taking place from 13 - 16 June in Amsterdam.

Eisai Co., Ltd. announced today that Eisai has received approval from “Science Based Targets Initiative” for Eisai’s mid and long-term targets for greenhouse gas reduction.

The funds will be used to partially support a Phase II clinical trial of T3D-959, the company’s novel treatment for Alzheimer’s disease.

The FDA extended the indication for Gattex to pediatric patients one year of age and older with short bowel syndrome.

Syncona, a London-based healthcare investment company, committed £34 million and UCL Technology Fund invested £1 million.

Cristal Therapeutics, a clinical-stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, today announced three upcoming poster presentations that highlight CPC634 positive data from its three phase 1 safety and biodistribution studies at the ASCO 2019 meeting, Chicago, Illinois May 31st - June 4th.

Hong Kong is known around the world for its financial might, iconic skyline and international outlook. But it might not be long before the city is known for something totally outside its traditional realm: cutting-edge healthcare solutions.

Biom’up is providing for the first time, full-year 2019 guidance for global sales of HEMOBLAST Bellows in the range of €4.0-4.5 million.

Auris Medical Holding Ltd. announced that it has received written notification from the Nasdaq Hearings Panel notifying the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550 for continued listing on The Nasdaq Capital Market.